Clinical Trial Update: RHPRG4 FOR THE TREATMENT OF OCULAR GRAFT-VERSUS-HOST DISEASE (OGVHD) [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial of RHPRG4 for ocular graft-versus-host disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ocular Graft-versus-host Disease

Drugs mentioned

• RHPRG4

Snippet

Sponsor: Lubris Bio Pty Ltd | Conditions: Ocular Graft-versus-host Disease | Phase 1, Phase 2 | Status: TERMINATED